Status:
UNKNOWN
Asia Glaucoma Registry
Lead Sponsor:
The University of Hong Kong
Conditions:
POAG
Eligibility:
All Genders
18+ years
Brief Summary
Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia, there is a need to ensure optimal management of t...
Detailed Description
Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia \[Tham et al, 2014\]. It is well established that ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of POAG or PACG
- Age ≥18 years at diagnosis.
- Have reliable VF tests obtained from Humphrey Field Analyzer (HFA) using the same testing strategy on average once a year over 6-7 years backward in at least one eye (the included eye must have evidence of glaucoma as defined above). A reliable VF test has fixation losses ≤20% and false positive errors ≤15%. All criteria mentioned above must be met for inclusion into the study. Both eyes will be included if both eyes meet the inclusion criteria.
Exclusion
- Secondary causes of glaucoma (e.g. uveitic glaucoma, neovascular glaucoma, traumatic glaucoma, exfoliative glaucoma, pigmentary glaucoma, phacomorphic glaucoma, malignant glaucoma)
- Any neurological disease that may result in VF loss (e.g. stroke)
- History of optic neuropathy other than glaucoma (including those related to thyroid eye disease);
- Prior retinal surgery.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05278299
Start Date
October 1 2021
End Date
September 30 2023
Last Update
March 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leung Kai Shun
Hong Kong, Hong Kong